Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie; Agios Pharmaceuticals, Inc.; Astellas; AstraZeneca; BeiGene, Ltd.; Celgene Corporation; Daiichi Sankyo, Inc.; GlaxoSmithKline; Karyopharm; Kite Pharma, Inc.; Novartis Pharmaceuticals Corporation; Oncopeptides, Inc.; Pfizer Inc.; Sanofi Genzyme; Seattle Genetics, Inc.; Servier Pharmaceuticals, LLC.; Takeda Oncology; and Verastem, Inc.

Community Practice Connections™: 24th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

Release Date: May 29, 2020
Expiration Date: May 29, 2021

Activity Overview

Community Practice Connections™: 24th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma consists of a series of interactive clinical vignettes, short video interviews with leading experts in hematologic malignancies, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Acknowledgement of Support

This activity is supported by educational grants from AbbVie; Agios Pharmaceuticals, Inc.; Astellas; AstraZeneca; BeiGene, Ltd.; Celgene Corporation; Daiichi Sankyo, Inc.; GlaxoSmithKline; Karyopharm; Kite Pharma, Inc.; Novartis Pharmaceuticals Corporation; Oncopeptides, Inc.; Pfizer Inc.; Sanofi Genzyme; Seattle Genetics, Inc.; Servier Pharmaceuticals, LLC.; Takeda Oncology; and Verastem, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational activity is intended for community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, investigators, and other health care professionals interested in the treatment of hematologic malignancies may also participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Evaluate current and emerging biomarkers to determine risk and choose therapy for patients with hematologic malignancies
  • Apply key clinical trial data on current and emerging treatment approaches for the management of patients with hematologic malignancies
  • Assess approaches to mitigate and manage treatment-related adverse events in patients with hematologic malignancies
  • Explain recent clinical trial results on emerging therapeutic approaches for patients with hematologic malignancies
  • Describe clinical implications of evolving therapeutic paradigms in hematologic malignancies

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Jorge E. Cortes, MD
Jorge E. Cortes, MD
Director, Georgia Cancer Center
Eminent Scholar, Georgia Research Alliance
Augusta University
Augusta, GA

Disclosures: Grant Research Support: Bristol Myers Squibb, Novartis, Pfizer, Sun Pharma, Takeda; Consultant: Bristol Myers Squibb, Novartis, Pfizer, Takeda.

Sagar Lonial, MD, FACP
Sagar Lonial, MD, FACP
Professor, Emory School of Medicine
Chair, Department of Hematology & Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, GA

Disclosures: Consultant: Bristol Myers Squibb, Celgene, Janssen, Merck, Millennium Pharmaceuticals, Novartis, Onyx Pharmaceuticals, Sanofi.

Sonali M. Smith, MD
Sonali M. Smith, MD
Elwood V. Jensen Professor in Medicine
Interim Chief, Section of Hematology/Oncology
Director, Lymphoma Program
The University of Chicago Medicine
Chicago, IL

Disclosures: Consultant: Bayer, TG Therapeutics; Other: Educational Lectures: Genentech, Kite Pharma.

Jennifer A. Woyach, MD
Jennifer A. Woyach, MD
Associate Professor, Division of Hematology
The Ohio State University Medical Center
Columbus, OH

Disclosures: Grant Research Support: AbbVie Inc, Loxo Oncology, Janssen, Pharmacyclics, Karyopharm Therapeutics, MorphoSys AG, Verastem; Consultant: Janssen, Pharmacyclics, AstraZeneca, ArQule.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
3031
Filter By